Galena Biopharma (GALE) Shares are Down -2.37%

Galena Biopharma (GALE) : During the past 4 weeks, traders have been relatively bearish on Galena Biopharma (GALE), hence the stock is down -5.29% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.72% relative to the S&P 500. The 4-week change in the price of the stock is -5.49% and the stock has fallen -2.37% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 3.61% and the fifty day Moving Average is 44.64%. Galena Biopharma, Inc. has dropped 75.71% during the last three month period . Year-to-Date the stock performance stands at -71.41%.


Galena Biopharma (NASDAQ:GALE): stock turned positive on Friday. Though the stock opened at $0.422, the bulls momentum made the stock top out at $0.45 level for the day. The stock recorded a low of $0.4155 and closed the trading day at $0.4202, in the green by 1.30%. The total traded volume for the day was 3,215,753. The stock had closed at $0.4148 in the previous days trading.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.